دورية أكاديمية
CD169+ Subcapsular Macrophage Role in Antigen Adjuvant Activity.
| العنوان: | CD169+ Subcapsular Macrophage Role in Antigen Adjuvant Activity. |
|---|---|
| المؤلفون: | Lisk C; Section of Infectious Diseases, Department of Medicine, Boston Medical Center, Boston, MA, United States., Yuen R; Department of Microbiology, Boston University School of Medicine, Boston, MA, United States., Kuniholm J; Department of Microbiology, Boston University School of Medicine, Boston, MA, United States., Antos D; Department of Microbiology and Immunology, University of Pittsburgh School of Medicine, Pittsburgh, PA, United States., Reiser ML; DRK-Blutspendedienst, BaWü-Hessen gGmbH, Frankfurt, Germany., Wetzler LM; Section of Infectious Diseases, Department of Medicine, Boston Medical Center, Boston, MA, United States.; Department of Microbiology, Boston University School of Medicine, Boston, MA, United States. |
| المصدر: | Frontiers in immunology [Front Immunol] 2021 Mar 18; Vol. 12, pp. 624197. Date of Electronic Publication: 2021 Mar 18 (Print Publication: 2021). |
| نوع المنشور: | Journal Article; Research Support, N.I.H., Extramural |
| اللغة: | English |
| بيانات الدورية: | Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101560960 Publication Model: eCollection Cited Medium: Internet ISSN: 1664-3224 (Electronic) Linking ISSN: 16643224 NLM ISO Abbreviation: Front Immunol Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: [Lausanne : Frontiers Research Foundation] |
| مواضيع طبية MeSH: | Immunogenicity, Vaccine*, Adjuvants, Immunologic/*pharmacology , Alum Compounds/*pharmacology , Macrophages/*drug effects , Oligodeoxyribonucleotides/*pharmacology , Ovalbumin/*pharmacology , Porins/*pharmacology , Sialic Acid Binding Ig-like Lectin 1/*metabolism , Toll-Like Receptors/*agonists, Animals ; Clodronic Acid/pharmacology ; Dendritic Cells, Follicular/drug effects ; Dendritic Cells, Follicular/immunology ; Dendritic Cells, Follicular/metabolism ; Immunoglobulin G/blood ; Macrophages/immunology ; Macrophages/metabolism ; Mice, Inbred C57BL ; Mice, Knockout ; Oligodeoxyribonucleotides/immunology ; Ovalbumin/immunology ; Porins/immunology ; Sialic Acid Binding Ig-like Lectin 1/genetics ; Signal Transduction ; Toll-Like Receptors/metabolism ; Vaccination ; Mice |
| مستخلص: | Vaccines have played a pivotal role in improving public health, however, many infectious diseases lack an effective vaccine. Controlling the spread of infectious diseases requires continuing studies to develop new and improved vaccines. Our laboratory has been investigating the immune enhancing mechanisms of Toll-like receptor (TLR) ligand-based adjuvants, including the TLR2 ligand Neisseria meningitidis outer membrane protein, PorB. Adjuvant use of PorB increases costimulatory factors on antigen presenting cells (APC), increases antigen specific antibody production, and cytokine producing T cells. We have demonstrated that macrophage expression of MyD88 (required for TLR2 signaling) is an absolute requirement for the improved antibody response induced by PorB. Here-in, we specifically investigated the role of subcapsular CD169+ marginal zone macrophages in antibody production induced by the use of TLR-ligand based adjuvants (PorB and CpG) and non-TLR-ligand adjuvants (aluminum salts). CD169 knockout mice and mice treated with low dose clodronate treated animals (which only remove marginal zone macrophages), were used to investigate the role of these macrophages in adjuvant-dependent antibody production. In both sets of mice, total antigen specific immunoglobulins (IgGs) were diminished regardless of adjuvant used. However, the greatest reduction was seen with the use of TLR ligands as adjuvants. In addition, the effect of the absence of CD169+ macrophages on adjuvant induced antigen and antigen presenting cell trafficking to the lymph nodes was examined using immunofluorescence by determining the relative extent of antigen loading on dendritic cells (DCs) and antigen deposition on follicular dendritic cells (FDC). Interestingly, only vaccine preparations containing PorB had significant decreases in antigen deposition in lymphoid follicles and germinal centers in CD169 knockout mice or mice treated with low dose clodronate as compared to wildtype controls. Mice immunized with CpG containing preparations demonstrated decreased FDC networks in the mice treated with low dose clodronate. Conversely, alum containing preparations only demonstrated significant decreases in IgG in CD169 knockout mice. These studies stress that importance of subcapsular macrophages and their unique role in adjuvant-mediated antibody production, potentially due to an effect of these adjuvants on antigen trafficking to the lymph node and deposition on follicular dendritic cells. Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. (Copyright © 2021 Lisk, Yuen, Kuniholm, Antos, Reiser and Wetzler.) |
| References: | Blood. 2011 May 19;117(20):5403-12. (PMID: 21444914) PLoS Pathog. 2012;8(11):e1003001. (PMID: 23144616) Viruses. 2017 Jul 13;9(7):. (PMID: 28703784) Elife. 2016 Aug 03;5:. (PMID: 27487469) Vaccines (Basel). 2015 Apr 16;3(2):320-43. (PMID: 26343190) Nature. 2007 Nov 1;450(7166):110-4. (PMID: 17934446) Am J Epidemiol. 2011 Dec 1;174(11 Suppl):S16-22. (PMID: 22135390) Semin Immunol. 2018 Oct;39:14-21. (PMID: 29801750) J Infect Dis. 1999 Sep;180(3):755-61. (PMID: 10438364) Protein Expr Purif. 2005 Dec;44(2):136-46. (PMID: 16027004) Semin Immunol. 2008 Feb;20(1):14-25. (PMID: 18261920) Blood. 2014 Jan 9;123(2):208-16. (PMID: 24255917) Vaccine. 2009 Dec 30;27 Suppl 6:G3-8. (PMID: 20006137) Immunol Cell Biol. 2016 Jul;94(6):538-42. (PMID: 26860369) Front Immunol. 2014 Sep 25;5:461. (PMID: 25309543) J Immunol. 2006 Feb 15;176(4):2373-80. (PMID: 16455995) Dimens Crit Care Nurs. 2017 May/Jun;36(3):145-147. (PMID: 28375989) Nat Immunol. 2009 Jul;10(7):786-93. (PMID: 19503106) Trends Immunol. 2019 Jan;40(1):35-48. (PMID: 30502023) Hum Vaccin Immunother. 2019;15(11):2778-2781. (PMID: 31112447) N Engl J Med. 1998 Jul 23;339(4):209-15. (PMID: 9673298) Rev Infect Dis. 1987 Sep-Oct;9 Suppl 5:S512-6. (PMID: 3317747) Front Immunol. 2017 Mar 03;8:225. (PMID: 28316602) Eur J Immunol. 2015 Mar;45(3):747-57. (PMID: 25487358) Nat Immunol. 2010 May;11(5):373-84. (PMID: 20404851) Nat Immunol. 2007 Sep;8(9):992-1000. (PMID: 17660822) Nature. 1988 Jul 21;334(6179):255-8. (PMID: 2456466) Bull World Health Organ. 2008 Feb;86(2):140-6. (PMID: 18297169) Proc Natl Acad Sci U S A. 2017 Apr 18;114(16):4031-4033. (PMID: 28396427) J Immunol. 2009 Sep 15;183(6):3634-41. (PMID: 19710456) Clin Infect Dis. 2000 Dec;31(6):1504-7. (PMID: 11096024) PLoS One. 2013 Dec 11;8(12):e82171. (PMID: 24349212) J Infect Dis. 2003 May 1;187(9):1349-59. (PMID: 12717615) Vaccine. 2018 Nov 29;36(50):7689-7699. (PMID: 30381152) Science. 2015 Feb 6;347(6222):667-72. (PMID: 25657250) J Immunol. 2016 Dec 1;197(11):4351-4359. (PMID: 27794001) J Clin Invest. 2016 Mar 1;126(3):799-808. (PMID: 26928033) Immunobiology. 1999 Dec;201(2):272-82. (PMID: 10631576) J Biol Response Mod. 1987 Apr;6(2):99-107. (PMID: 3585413) Immunity. 2011 Jan 28;34(1):85-95. (PMID: 21194983) Nat Immunol. 2011 Dec 16;13(1):13-4. (PMID: 22179272) AIDS. 2006 Apr 24;20(7):1039-49. (PMID: 16603857) Curr Top Microbiol Immunol. 2006;311:1-16. (PMID: 17048703) Trends Immunol. 2012 Feb;33(2):66-70. (PMID: 22192781) Front Immunol. 2019 Feb 28;10:347. (PMID: 30891035) Proc Natl Acad Sci U S A. 2015 Apr 28;112(17):5461-6. (PMID: 25922518) Science. 1987 May 22;236(4804):944-7. (PMID: 3107127) Eur J Immunol. 1993 Aug;23(8):1762-70. (PMID: 8102100) Front Immunol. 2020 Jun 19;11:1254. (PMID: 32636846) Immunity. 2010 Oct 29;33(4):492-503. (PMID: 21029960) Nat Med. 2013 Dec;19(12):1597-608. (PMID: 24309663) Front Immunol. 2015 Mar 13;6:114. (PMID: 25821451) Mol Immunol. 2012 Mar;50(3):172-6. (PMID: 22189408) Trends Immunol. 2016 Oct;37(10):716. (PMID: 27595229) Cell. 2007 Nov 16;131(4):641-3. (PMID: 18022354) J Immunol. 1983 Oct;131(4):1714-27. (PMID: 6619542) J Microsc. 2006 Dec;224(Pt 3):213-32. (PMID: 17210054) Science. 1996 Apr 5;272(5258):50-3. (PMID: 8600536) Sci Rep. 2017 Apr 7;7(1):736. (PMID: 28389664) Cell Rep. 2017 Nov 28;21(9):2515-2527. (PMID: 29186688) PLoS One. 2011 Feb 16;6(2):e16827. (PMID: 21359217) Biochem Soc Trans. 2007 Dec;35(Pt 6):1468-72. (PMID: 18031247) Hum Vaccin Immunother. 2012 Jul;8(7):971-8. (PMID: 22485046) J Immunol. 2016 Dec 1;197(11):4413-4424. (PMID: 27793997) Curr Opin Immunol. 2016 Aug;41:85-90. (PMID: 27392183) J Exp Med. 1968 Feb 1;127(2):263-76. (PMID: 5635379) Cell Immunol. 2002 Jul-Aug;218(1-2):74-86. (PMID: 12470615) Proc Natl Acad Sci U S A. 2014 Aug 26;111(34):12288-93. (PMID: 25136130) |
| معلومات مُعتمدة: | R01 AI040944 United States AI NIAID NIH HHS |
| فهرسة مساهمة: | Keywords: Neisseria; PorB; TLR-ligand based adjuvants; TLR2; adjuvants; antibody production; antigen deposition; follicular dendritic cells |
| المشرفين على المادة: | 0 (Adjuvants, Immunologic) 0 (Alum Compounds) 0 (CpG ODN 1826) 0 (Immunoglobulin G) 0 (Oligodeoxyribonucleotides) 0 (Porins) 0 (Sialic Acid Binding Ig-like Lectin 1) 0 (Siglec1 protein, mouse) 0 (Toll-Like Receptors) 0 (porin protein, Neisseria) 0813BZ6866 (Clodronic Acid) 34S289N54E (aluminum sulfate) 9006-59-1 (Ovalbumin) |
| تواريخ الأحداث: | Date Created: 20210405 Date Completed: 20210914 Latest Revision: 20240226 |
| رمز التحديث: | 20240226 |
| مُعرف محوري في PubMed: | PMC8012505 |
| DOI: | 10.3389/fimmu.2021.624197 |
| PMID: | 33815376 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 1664-3224 |
|---|---|
| DOI: | 10.3389/fimmu.2021.624197 |